Palbociclib (Ibransa®): new possibilities of hormone therapy for luminal her2-negative metastatic breast cancer
Abstract
Hormonal therapy is the main treatment for estrogen receptor positive (ER+) HER 2-negative metastatic breast cancer. Cyclin-dependent kinases 4 and 6 (CDK4/6) are regulators of cell transition from G1 phase to S phase of the cell cycle. The activity of CDK4/6 is increased in the cells of the ER+ breast cancer. CDK4/6 are key targets of signal pathways from the estrogen receptors. Palbociclib is a first-in-class oral inhibitor of CDK4/6. The article presents results of two large randomized phase III trials PALOMA-2 and PALOMA-3, including patients with ER+ HER 2-negative advanced breast cancer. Palbociclib in combination with letrozole significantly improved progression-free survival (PFS) compared with letrozole alone as first-line treatment of advanced breast cancer. Adding palbociclib to fulvestrant results in longer PFS than fulvestrant alone in women with advanced breast cancer as second-line treatment.
About the Authors
I. A. Koroleva
Samara Medical University ‘REAVIZ’
Russian Federation
Russian Federation
M. V. Kopp
Samara Medical University ‘REAVIZ’
Russian Federation
Russian Federation
References
1. Каприн А. Д., Старинский В. В., Петрова Г. В. (ред.). Состояние онкологической помощи населению России в 2015 году.- М.: МНИОИ им. П. А. Герцена филиал ФГБУ «НМИРЦ» Минздрава России, 2016. - 236 с.
2. Saad E., Katz A., Machado K., Buyse M. Post-progression survival (PPS) and overall survival (OS) according to treatment type in contemporary phase III trials in advanced breast cancer (ABC). SABCS2009; abstr. 5116.
3. Dawood S., Broglio K., Gonzalez-Angulo A. M. et al. Trends in survival over the past two decades among white and black patients with newly diagnosed stage IV breast cancer. J. Clin. Oncol. 2008; 26: 4891-4898.
4. Стенина М. Б., Жукова Л. Г., Королева И. А. и соавт. Практические рекомендации по лекарственному лечению инвазивного рака молочной железы // Злокачественные опухоли. - 2016. - № 4. Спецвыпуск 2. - С. 97-122.
5. Cleator S. J., Ahamed E., Coombes R. C., Palmieri C. A 2009 update on the treatment of patients with hormone receptor-positive breast cancer // Clin. Breast Cancer. - 2009/ - № 9 / - Suppl. 1. Р. 6-17.
6. Ingle J. N., Krook J. E., Green S. J. et al. Randomized trial of bilateral oophorectomy versus tamoxifen in premenopausal women with metastatic breast cancer // J. Clin. Oncol. - 1986. - № 4. - P. 178-185.
7. Veronesi U., Pizzocaro G., Rossi A. Oophorectomy for advanced carcinoma of the breast // Surg. Gynecol. Obstet. - 1975. - T. 141. - P. 569-570.
8. Conte C. C., Nemoto T., Rosner D. et al. Therapeutic oophorectomy in metastatic breast cancer // Cancer. - 1989. - T. 64. - P. 150-153.
9. Oriana S., Bohm S., Baeli A. et al. Clinical response and survival according to estrogen receptor levels after bilateral ovariectomy in advanced breast cancer // Eur. J. Surg. Oncol. - 1989. T. 15. - P. 39-42.
10. Wilcken N., Hornbuckle J., Ghersi D. Chemotherapy alone versus endocrine therapy alone for metastatic breast cancer. Cochrane Database Syst. Rev. 2003; CD002747.
11. Australian and New Zealand Breast Cancer Trial Groups, Clinical Oncological Society of Australia. A randomised trial in post-menopausal patients with advanced breast cancer comparing endocrine and cytotoxic therapy given sequentially or in combination // J. Clin. Oncol. - 1986. - № 4. - P. 186-193.
12. Mehta R. S., Barlow W. E., Albain K. S., et al. Combination anastrozole and fulvestrant in metastatic breast cancer // N. Engl. J. Med. - 2012. - № 367. - P. 435-444.
13. Fry D. W., Harvey P. J., Keller P. R., et al. Specific Inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts // Molecular Cancer Therapeutics. 2004. - № 3. - P. 1427-1437.
14. Finn R. S., Dering J., Conklin D. et al. PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro // Breast Cancer Res. 2009. - № 11 (5). - P. 77.
15. Finn R. S., Crown J. P., Lang I., et al. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozol versus letrozol alone as first-line treatment of oestrogen receptor-positive, HER 2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomized phase 2 study // Lancet Oncology. - 2015. - № 16. - P. 25-35.
16. Finn R. S., Martin M., Jones S. E., et al. PALO-MA-2: primary results from a phase iii trial of palbociclib (p) with letrozole (l) compared with letrozole alone in postmenopausal women with er+/her2- advanced breast cancer (abc) // J. Clin. Oncol. - 2016. - № 34 (suppl.; abstr 507).
17. Turner N. C., Ro J., Andre F., et al. Palbociclib in hormone-receptor-positive advanced breast cancer // N. Engl. J. Med. - 2015. - № 373. - P. 209-219.
18. Cristofanilli M., Turner N. C., et al. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER 2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): fi nal analysis of the multicentre, double-blind, phase randomised controlled trial // Lancet Oncol. - 2016. - № 17 (4). - P. 425-439.
19. Loibl S., Turner N. C., Ro J., et al. Palbociclib (PAL) in combination with fulvestrant (F) in pre-/peri-menopausal (PreM) women with metastatic breast cancer (MBC) and prior progression on endocrine therapy - results from Paloma-3 // J. Clin. Oncol. - 2016. - № 34 (suppl.; abstr. 524).
20. National Comprehensive Cancer: NCCN Clinical Practice Guidelines in Oncology. Breast Cancer 2.2016. https://www.nccn.org.
21. Rugo H. S., Rumle B., Macrae E. et al. Endocrine Therapy for Hormone Receptor-Positive Metastatic Breast Cancer: American Society of Clinical Oncology Guideline // J. Clin. Oncol. - 2016. - 34, № 25. - Р. 3069-3103.
Review
For citations:
Koroleva I.A., Kopp M.V. Palbociclib (Ibransa®): new possibilities of hormone therapy for luminal her2-negative metastatic breast cancer. Medical alphabet. 2017;1(16):6-11. (In Russ.)
Views:
2458
Email this article 